Therapeutic response to corticosteroids in a critically ill patient with COVID-19

KaiGe, Wang; Tan, Fen; Zhou, Rui; Liu, Dan; Ni, Zhenyu; Liu, Jiasheng; Luo, Fengming

doi:10.1097/md.0000000000021597

Cited by 11 publications

(14 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The outcome of CSs among the treated COVID-19 patients is found to vary due to different doses. To mitigate the uncertainty, CSs could be used at a moderate dose for a shorter period [ 91 ]. A detailed medical history of the patients should be collected before treating with CSs to minimize CSs induced comorbidity.…”

Section: Recommendations To Minimize the Side Effects Of Css Treatment In Covid-19 Patientsmentioning

confidence: 99%

Corticosteroids for COVID-19: worth it or not?

Akter

Araf

2021

Mol Biol Rep

View full text Add to dashboard Cite

Pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced COVID-19 implied the presence of excessive proinflammatory cytokines and chemokines in patients causing significant morbidity and mortality. To diminish systemic hyper inflammation, a few physicians and researchers have utilized corticosteroids. Corticosteroid implementation has increased after the publication of interim guidelines regarding corticosteroid use in COVID-19 patients by WHO, despite the remaining controversies regarding long-term side effects and disease progression capability of corticosteroids. In different studies, the implementation of corticosteroids on COVID-19 patients revealed controversial results, which require further intensive research. This review will present the current outcomes and possibilities of using corticosteroids to treat COVID-19 patients.

show abstract

Section: Recommendations To Minimize the Side Effects Of Css Treatment In Covid-19 Patientsmentioning

confidence: 99%

Corticosteroids for COVID-19: worth it or not?

Akter

Araf

2021

Mol Biol Rep

View full text Add to dashboard Cite

show abstract

“…[ 35 ] Patients with severe conditions were more likely to require glucocorticoids. [ 36 ] Our findings showed that using glucocorticoid could reduce the mortality of severe COVID-19 patients.…”

Section: Discussionmentioning

confidence: 75%

The effect of glucocorticoids on mortality in severe COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

Background: Since the start of the coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need for effective therapies for patients with COVID-19. In this study, we aimed to assess the therapeutic efficacy of glucocorticoids in severe COVID-19. Methods: A systematic literature search was performed across PubMed, Web of Science, EMBASE, and the Cochrane Library (up to June 26, 2021). The literature investigated the outcomes of interest were mortality and invasive mechanical ventilation. Results: The search identified 13 studies with 6612 confirmed severe COVID-19 patients. Our meta-analysis found that using glucocorticoids could significantly decrease COVID-19 mortality (hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.45–0.79, P < .001), relative to non-use of glucocorticoids. Meanwhile, using glucocorticoids also could significantly decrease the risk of progression to invasive mechanical ventilation for severe COVID-19 patients (HR = 0.69, 95% CI 0.58–0.83, P < .001). Compared with using dexamethasone (HR = 0.68, 95% CI 0.50–0.92, P = .012), methylprednisolone use had a better therapeutic effect for reducing the mortality of patients (HR = 0.35, 95% CI 0.19–0.64, P = .001). Conclusion: The result of this meta-analysis showed that using glucocorticoids could reduce mortality and risk of progression to invasive mechanical ventilation in severe COVID-19 patients.

show abstract

“…The ocular findings of this patient improved following topical and systemic corticosteroid therapy which was tapered over a period of six weeks. A recent case report 17 showed that early use of corticosteroids at a moderate dose for a short course may enhance recovery of a COVID-19 patient. In this context, we support timely and appropriate use of corticosteroids in COVID-19 cases taking into consideration uveitis severity, systemic comorbidities, age, and lens status.…”

Section: Discussionmentioning

confidence: 99%

Clinical Profile of COVID-19 Patients Presenting with Uveitis – A Short Case Series

Iriqat¹,

Yousef²,

Ereqat³

2021

IMCRJ

View full text Add to dashboard Cite

Purpose To present the clinical features of anterior, intermediate and posterior uveitis in patients with COVID-19 and to increase the awareness of the treating physicians to refer patients with COVID-19 who have eye symptoms for ophthalmic exam, in order to diagnose as early as possible and prevent vision-threatening complications. Methods Retrospective observational case reports. Results We report three cases of COVID-19 patients who developed uveitis during or after the course of their sickness with COVID-19. All patients underwent a detailed eye examination, relevant history and investigations did not prove any other cause of uveitis. Conclusion This report presents novel data on the course of subjects with uveitis during the COVID-19 pandemic. Intermediate and posterior uveitis warrant further evaluation with differential diagnosis supported by laboratory tests due to the association with systemic diseases and risk of permanent vision loss. Iridocyclitis, intermediate, and posterior uveitis treatment should be guided by ophthalmologists, particularly uveitis specialists, when possible.

show abstract

Therapeutic response to corticosteroids in a critically ill patient with COVID-19

Cited by 11 publications

References 9 publications

Corticosteroids for COVID-19: worth it or not?

Corticosteroids for COVID-19: worth it or not?

The effect of glucocorticoids on mortality in severe COVID-19 patients

Clinical Profile of COVID-19 Patients Presenting with Uveitis – A Short Case Series

Contact Info

Product

Resources

About